Clinical Trial Update: Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is evaluating pucotenlimab with lenvatinib and temozolomide for resectable acral melanoma (Stage IIB/III); the study status is not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Melanoma
• Melanoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pucotenlimab
• Temozolomide (Temozolomide)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Melanoma (Skin Cancer) | Phase 2 | Status: NOT_YET_RECRUITING